Skip to main content

Table 1 Patient characteristics

From: Computed tomography texture analysis for the prediction of lateral pelvic lymph node metastasis of rectal cancer

 

Total (n = 25)

LPLNM (n = 8)

Non-LPLNM (n = 17)

p

Age, years

63 (44–84)

65.5 (44–84)

76 (44–81)

0.662

Sex (male/female)

20/5

7/1

13/4

1.000

BMI, kg/m2

22.4 (18.6–28.0)

22.85 (19.4–28.0)

22.4 (18.6–26.7)

0.641

ASA-PS (1/2/3)

11/11/3

4/3/1

7/8/2

1.000

Abddominal surgical history

5 (20.0%)

2 (25.0%)

3 (17.6%)

1.000

Preoperative chemotherapy

4 (16.0%)

3 (17.6%)

1 (12.5%)

1.000

Preoperative chemoradiotherapy

5 (20.0%)

2 (11.8%)

3 (37.5%)

0.283

Tumor

 pT (1/2/3/4/LPLNR)

3/5/13/3/1

0/3/2/2/1

3/2/11/1/0

0.049

 pN (0/1/2/3/LPLNR)

12/5/0/7/1

0/0/7/1

12/5/0/0

 > 0.001

 cM (0/1/LPLNMR)

21/3/1

7/0/1

14/3/0

0.188

 Differentiation (moderate or high/low)

22/3

5/3

17/0

0.024

 L (0/1/X)

7/16/2

1/5/2

6/11/0

0.108

 V (0/1/X)

7/15/3

3/3/2

4/12/1

0.263

Surgery

 Procedure (AR/ISR/APR/TPE)

12/3/9/1

6/0/2/0

3/3/10/1

0.051

 Robot/Laparoscopy

18/7

6/2

12/5

1.000

 taTME

22 (88.0%)

16 (75.0%)

6 (94.1%)

0.231

 Diverting stoma

14 (56.0%)

   

 Operative time, min

479 (240–867)

549.5 (417–678)

413 (240–867)

0.140

 Blood loss, ml

65 (0–760)

68 (30–160)

65 (0–760)

0.502

 Dissected lateral lymph nodes

12 (2–24)

11 (5–23)

12 (2–24)

0.930

  1. LPLNM Lateral lymph node metastasis, BMI Body mass index, ASA-PS American Society of anesthesiologists physical status, pT Pathological tumor depth of invasion, LPLNR Lateral pelvic lymph node metastatic recurrence, pN Pathological lymph node metastasis, cM Clinical distant metastasis, CR Complete response, L Lymphatic invasion, V Venous invasion, AR Anterior resection, ISR Intersphincteric resection, APR Abdominoperineal resection, TPE Total pelvic exenteration, taTME Transanal total mesorectal excision